Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

James A. Geraghty net worth and biography

James Geraghty Biography and Net Worth

Director of Fulcrum Therapeutics

James (Jim) Geraghty is an industry leader with over 30 years of strategic and leadership experience, centered around biotechnology companies developing and commercializing innovative therapies. Jim served as an entrepreneur in residence at Third Rock Ventures from 2013-2016. He was previously senior vice president, North America strategy and business development at Sanofi, which he joined upon its acquisition of Genzyme. Jim spent almost 20 years at Genzyme, where his roles included senior vice president of international development, president of Genzyme Europe, and founder, president and CEO of Genzyme Transgenics. Jim serves as chairman of the boards of Idera Pharma, Pieris Pharma, and Orchard Therapeutics, and on the board of Voyager Therapeutics. He started his career in healthcare strategy consulting at Bain and Company. A graduate of the Yale Law School, he holds a master’s degree from the University of Pennsylvania and a bachelor’s from Georgetown University.

What is James A. Geraghty's net worth?: The estimated net worth of James A. Geraghty is at least $3.26 as of August 7th, 2024. Mr. Geraghty owns 1 shares of Fulcrum Therapeutics stock worth more than $3 as of November 5th. This net worth evaluation does not reflect any other assets that Mr. Geraghty may own. Learn More about James A. Geraghty's net worth.
How do I contact James A. Geraghty?: The corporate mailing address for Mr. Geraghty and other Fulcrum Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Fulcrum Therapeutics can also be reached via phone at (617) 651-8851 and via email at [email protected]. Learn More on James A. Geraghty's contact information.
Has James A. Geraghty been buying or selling shares of Fulcrum Therapeutics?: James A. Geraghty has not been actively trading shares of Fulcrum Therapeutics during the last quarter. Most recently, on Monday, June 28th, James A. Geraghty bought 10,000 shares of Fulcrum Therapeutics stock. The stock was acquired at an average cost of $9.16 per share, with a total value of $91,600.00. Following the completion of the transaction, the director now directly owns 90,714 shares of the company's stock, valued at $830,940.24. Learn More on James A. Geraghty's trading history.
Who are Fulcrum Therapeutics' active insiders?: Fulcrum Therapeutics' insider roster includes James Geraghty (Director), Robert Gould (Insider), Christopher Morabito (Insider), Curtis Oltmans (SVP), and Peter Thomson (CEO). Learn More on Fulcrum Therapeutics' active insiders.
Are insiders buying or selling shares of Fulcrum Therapeutics?: During the last year, insiders at the sold shares 2 times. They sold a total of 5,120 shares worth more than $59,071.84. The most recent insider tranaction occured on May, 7th when insider Greg Tourangeau sold 236 shares worth more than $1,831.36. Insiders at Fulcrum Therapeutics own 4.1% of the company. Learn More about insider trades at Fulcrum Therapeutics.
Information on this page was last updated on 5/7/2024.

James A. Geraghty Insider Trading History at Fulcrum Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/28/2021	Buy	10,000	$9.16	$91,600.00	90,714

James A. Geraghty Buying and Selling Activity at Fulcrum Therapeutics

Fulcrum Therapeutics Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.26

$3.13

$3.38

50 Day Range

MA: $4.68

$3.16

$8.87

2 Week Range

Now: $3.26

$2.87

$13.70

Volume

843,613 shs

Average Volume

586,241 shs

Market Capitalization

$203.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.24

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad